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Background: Alzheimer’s disease (AD), a progressive and degenerative disorder, has become one of the severe
problems among the aged population all over the world. To use cholinesterase inhibitor drugs has become the
most predominant treatment strategy for AD.
Results: A series of novel 1, 3-dihydroxyxanthone Mannich bases derivatives (1a ~ 4e) were synthesized, structure
elucidated and evaluated for anti-cholinesterase activity. The result showed that most of the target compounds
exhibited moderate to good inhibitory activities with the IC50 values at micromole level concentration against both
acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). The preliminary structure-activity indicated that:
(i) The alkoxy or alkenoxy substituents in the position 3 of xanthone have a positive influence on the inhibition
potency; (ii) types of dialkylamine methyl in position 2 of xanthone affected cholinesterase activities and AChE/
BuChE selectivity. Among them, 2-((diethylamino)methyl)-1-hydroxy-3-(3-methylbut-2-enyloxy)-9H-xanthen-9-one
showed potent inhibitory activity against AChE with the IC50 value of 2.61 ± 0.13 μM and the best inhibitory activity
against BuChE with the IC50 value of 0.51 ± 0.01 μM. The results of a mixed-type manner in enzyme kinetic experiment
and molecular docking study for 2-((diethylamino)methyl)-1-hydroxy-3-(3-methylbut-2-enyloxy)-9H-xanthen-9-one
demonstrated that the Mannich base derivatives were likely to bind to the active site (AS) and the peripheral anionic
site (PAS) of cholinesterases.
Conclusions: This study suggested that 1, 3-dihydroxyxanthone Mannich base derivatives were potential dual
inhibitors of both AChE and BuChE, which may be considered as a kind of novel drug candidates for treatment of AD.
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It is well known that there are two major forms of cholin-
esterases in the brain of mammals. One is acetylcholin-
esterase (AChE), it is a special enzyme to hydrolyze the
neurotransmitter acetylcholine (ACh). The other is
butyrylcholinesterase (BuChE), it is a pseudocholinesterase
that remains unanswered, which is less substrate specific
for ACh than AChE. However, its expressive level was
more abundant in the peripheral system. Both of the two
cholinesterase are found in neurons and glial cells as well* Correspondence: jiangkeq@sina.com; hshwang2002@126.com
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reproduction in any medium, provided the oras in neuritic plaques and tangles in Alzheimer disease
(AD) patients [1].
AD is the most common dementia occurs among the
elderly people. It is a progressive and neurodegenerative
disorder affects regions of the brain that control cogni-
tion, memory, language, speech and awareness [2,3]. The
two major pathological hallmarks of AD are the progres-
sive loss of cholinergic neural transmission, formation of
a beta-amyloid plaques (Aβ-plaques) that forms senile
plaques (SPs) and neurofibrillary tangles (NFTs) of
hyperphosphorylated tau protein [4,5]. Hence, two hy-
potheses including cholinergic and β-amyloid [6-8] were
developed to interpret this phenomena, which, in es-
sence, states that the cognitive decline in Alzheimer’s
disease is due (at least in part) to a loss of cholinergic
neurotransmission [9] and the deposition beta-amyloidtd. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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therapies are thought to be a pivotal strategy for the cure
of AD [10,11].
New findings show that both AChE and BuChE are
involved in the breakdown of acetylcholine in the brain.
Dual inhibition of these enzymes may increase the
efficacy of treatment and broaden the indications. It is
demonstrated that AChE has a key role in the acceler-
ation of Aβ-peptide deposition and promoting the
formation of Aβ-plaques in Alzheimer’s brain [12]. Re-
cent studies suggest that BuChE is present in key brain
areas and may also influence the aggregation of neuritic
β-amyloid (Aβ) plaques to form the neurofibrillary
plaques causing [13-15].
For clinical purposes, it is particularly important to
consider the fact that while brain AChE activity continu-
ously declines, BuChE activity increases continuously
during disease progression [16,17]. Clinical data is there-
fore mounting to suggest that the use of agents with the
ability to effectively inhibit BuChE as well as AChE may
represent an additional therapeutic strategy for the on-
going management of AD [18,19].
To date, there are many drugs had been approved and
licensed for curing this disease, such as rivastimine,
donepezil and galanthamine. At a certain extent, they are
generally considered as cholinesterase inhibitors. Although
these drugs share the same therapeutic class, they differ in
their pharmacology and pharmacokinetics and possess dif-
ferent degree side effects. Moreover, they just cure mild or
moderate degree of AD at the early stage, still no cure for
severe type of AD.
Xanthone, chemical name is dibenzo-γ-pyrone, is a
basic building block of active component of many natur-
ally medicinal plants. Its derivatives are broadly distrib-
uted in the nature, and with a wide range of biological
activities, such as anti-bacterial, anti-inflammatory, anti-
tumour and α-glucosidase inhibitory activities [20-23].
Xanthone derivatives as anti-cholinesterase agents have
been received significant attention in recent years. It was
reported that xanthone derivatives could inhibit AChE
and block the Acetylcholinesterase-induced β-Amyloid
aggregation [24-26]. However, there are few reports
about the research on xanthone derivates as dual inhibi-
tors of both AChE and BuChE. Recent research showed
that macluraxanthone exhibited several hydrophobic in-
teractions and hydrogen bonds with the amino acid resi-
dues of the PAS, AS and acyl-binding pocket of AChE
and BuChE [27]. Futhermore, Mannich bases have been
associated with increased biological potency [28]. So xan-
thone was used as a building block, and a series of
Mannich bases of 1, 3-dihydroxyxanthone analogues with
alkoxy and alkenoxy substituted at position 3 of xanthone
and dialkylamine methyl substituted at position 2 were
designed and synthesized as cholinesterase inhibitors,which possessed dual inhibitory activity to AChE as well
as BuChE. Their inhibitory effects on both AChE and
BuChE were evaluated. Furthermore, the enzyme kinetic
analysis and molecular docking studies were performed to
delineate their modes of inhibition.Results and discussion
Chemistry
The target compounds 1a ~ 1e, 2a ~ 2e, 3a ~ 3e, 4a ~ 4e
were synthesized according to the synthetic route
showed in Scheme 1. 1, 3-dihydroxyxanthone was firstly
obtained through the one pot reaction using salicylic
acid and phloroglucinol as raw material [29,30]. Then,
etherification of the hydroxyl in the position 3 of 1, 3-
dihydroxyxanthone was carried out under alkaline con-
dition, three kinds of intermediate compounds 2 ~ 4
with different substituents at position 3 were obtained
[31]. Finally, compounds 1 ~ 4 were reacted with formal-
dehyde and various secondary amines in methanol or
acid solution by the Mannich reaction, respectively
[32,33], yielded the corresponding Mannich bases of 1,
3-dihydroxyxanthone derivatives.
For the 1, 3-dihydroxyxanthone and the oxygenated
derivatives (2 ~ 4), 2- and 4-position are active sites and
the Mannich reaction may be processed in these two
position. In order to establish the exact position of sub-
stituents of the title compounds, we hypothesis that if
the reaction was carried out in the position 2, the H of
CH2 inducted by Mannich Reaction correlated with C-1
of xanthone ring in HMBC, if not the H of CH2 corre-
lated with C-4a. For validating the hypothesis, 2c was
subjected to HSQC and HMBC spectral analysis. The
data was shown in Table 1. It was not difficult to con-
firm the 1H NMR spectral assignments of 2c by analyz-
ing its coupling relation and comparing its 1H NMR
data with that of 1, 3-dihydroxyxanthone [34]. In 1H
NMR, the consecutive aromatic protons of A ring were
observed at 8.24 (d, J = 7.9 Hz, 1H), 7.35 (t, J = 7.5 Hz,
1H), 7.68 (t, J = 7.9 Hz, 1H), 7.40 (d, J = 8.4 Hz, 1H); the
only reserved proton of C ring was observed at 6.43 (s, 1H)
which indicated that one of the aromatic protons of C ring
(2- or 4- position) was replaced by the Mannich reaction
and the inducted CH2N groups were observed as singlet at
3.76 ppm. From HSQC, HMBC and also comparing its 13C
NMR data with that of 1, 3-dihydroxyxanthone [35], its 13C
NMR assignments could easy be appointed, in which C-1
and C-4a in xanthone core were observed at 161.70, 157.54
respectively. From the data of HMBC, we can observe that
the H of CH2N correlated with C-1 of xanthone ring, not
with C-4a, which confirmed that the Mannich reaction was
carried out in the position 2. The main connective found in
the HMBC was depicted in Figure 1. Other target com-
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Scheme 1 Synthetic route of 1, 3-dihydroxyxanthone mannich base derivatives.
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and IR.
Biological activity
The inhibitory activities of all the synthesized Mannich
bases of 1,3-dihydroxyxanthone derivatives against AChE
and BuChE in vitro were tested by slightly modified Ellman
method [36], using acetylthiocholine and butyrylthiocholine
iodide as substrates and with Galanthamine · HBr as the
reference standard. Inhibition potency of the title com-
pounds toward AChE and BuChE was displayed as IC50
values in Table 2.
From the data listed in the Table 2, we can clearly see
that most of the designed compounds exhibited moder-
ate to good inhibitory activities with the IC50 values at
micromole level concentration against both of the
enzymes.
Some preliminary structure-activity relationships
could be summarized as follows: Whether the variety
substituent of amido in the position 2 had influences on
anti-cholinesterase activity was firstly assessed. The
IC50 values were used to draw histogram (Figure 2). As
Figure 2 showed, diethylamine methyl in the position 2
of the xanthone exhibited the most potential inhibitory.
However, the presence of morpholino methyl showed
relatively poor inhibitory activity against both of the en-
zyme in most case, especially compound 1e, 2e, 3e didnot show any inhibition activity at 100 μМ against
BuChE. The influence order could be summarized as fol-
lows: diethylamine methyl ≈ dimethylamine methyl >
pyrrolidinyl methyl > piperidinyl methyl > morpholino
methyl against a-cetylcholinesterase activity and
diethylamino methyl > pyrrolidinyl methyl > piperidinyl
methyl > dimethylamine methyl > morpholino methyl
against butyrylcholinesterase activity.
The effects of various substituents in the position 3 were
subsequently investigated (Figure 3). Firstly, as for the in-
hibitory activity against AChE, methoxyl substitution
shows the most potent inhibitory, which is consistent with
a previous report describing that methoxyl was favorable,
although the former report focused on the coumarin moi-
ety [37]. The influence order is methoxyl > prenylated
oxyl > allyloxy > hydroxyl. Interestingly, as for the anti-
butyrylcholinesterase activity, increasing bulkiness of the
derivatives, which bear alkenoxy in the position 3 of xan-
thone exert higher potency. The most active inhibitor
against BuChE was 4b with IC50 value of 0.51 ± 0.01 μM,
which bears prenyl substituted in the position 3. It also
showed potent inhibitory activity against AChE with the
IC50 value of 2.61 ± 0.13 μM. This result was similar to the
Rivera-Becerril’s report [38], confirming the double bond
of the prenyl group is interacting as a specific π-hydrogen
bond acceptor with the enzyme. The influence order is
prenylated oxyl > allyloxy >methoxyl > hydroxyl. In order
Table 1 The NMR data of compound 2c








5 117.76 7.40 (d, J= 8.4 Hz, 1H) 117.74 121.19, 124.27
6 135.07 7.68 (t, J = 7.9 Hz, 1H) 135.07 126.27, 156.21
7 124.27 7.35 (t, J = 7.5 Hz, 1H) 124.27 117.76, 121.19





OCH3 56.37 3.92 (s, 3H) 56.37 165.67
CH2N 45.96 3.76 (s, 2H) 45.96 165.67, 161.70,
109.21, 54.24
1' and 4' 54.24 2.63 (brs, 4H) 54.24 23.81
2' and 3' 23.81 1.75 (brs, 4H) 23.81 23.81
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BuChE, the ligand binding sites are considered in both en-
zymes, such as active site and peripheral anionic site (PAS).
In terms of the active sites, it is known that the volume of
active site in BuChE is larger than AChE [39-41] and hence
can accommodate ligands with larger molecular structures.
In PAS, there are a number of hydrophobic amino acids,
which in AChE are largely aromatic amino acids while in
BuChE are largely aliphatic [42-44]. In general, the AChE
and BuChE inhibitory activities of etherified compounds
with alkyl group in the position 3 are better than those with
hydroxyl group. It suggests that hydrophobic circumstance
is importance for the anti-cholinesterase activities. The
substituents in the position 3 of xanthone show a positive
influence on the inhibition potency.Figure 1 Main connectivities found in the HMBC of
Compound 2c.From Table 2, we also could see that most of the title
compounds had BuChE/AChE selectivity index in the
range of 0.1-0.8, which suggested that these compounds
were potential dual inhibitors of both cholinesterases
and showed more inhibitory potency toward BuChE.
Because bivalent ChE inhibitors or selective BuChE
inhibitors represent a new therapeutic strategy for the
on-going management of AD [18,19], thus they might
become a novel kind of potential drug candidates for
AD treatment.
The inhibition modes of both cholinesterases caused
by the selected potent compound 4b were investigated
by the graphical analysis of steady-sate inhibition data
(Figure 4). Reciprocal plots (lineweaver-Burk plots) de-
scribing compounds 4b inhibition showed that the point
of the curves intersect at the secondary quadrant. This
pattern indicated the mixed-type inhibition. The results
revealed that these compounds were likely to bind both
of the active site and PAS of both cholinesterases.
In order to further investigate the binding modes of
Mannich bases derivatives with cholinesterases, we car-
ried out molecular docking studies for the selected po-
tent compound 4b by Surflex-Dock suite implemented
in SYBYL 8.0 software. The PDB codes of 3D crystal
structures of human AChE and BuChE are 1EVE and
1P0I, respectively. As shown in Figure 5A, the most en-
ergetically favorable binding mode of compound 4b at
the active site of AChE comes into a free binding energy
of −7.14 kcal/mol. The MOLCAD surface modeling with
cavity depth potential shows that compound 4b extends
into the deep cavity of the binding pocket of AChE
(Figure 5B). Compound 4b occupied to the central
hydrophobic region of the binding pocketed arranged by
Tyr70, Tyr121, Trp279 and Phe290. It is clearly demon-
strated that compound 4b extends from the anionic
subsite of the active site near Trp84 to PAS region near
Trp279. Besides, aromatic ring of compound 4b also
forms π-π interactions with Trp279 (Figure 5C). More-
over, the dendrimer-shaped motif at the aromatic ring of
compound 4b may effectively prevent the interaction of
catalytic triad of AChE with substrate. These interaction
and occupation of compound 4b with the subsites of
AChE explains its mixed inhibition type.
On the other hand, Figure 6A illustrates that the binding
energy of the most energetically favorable binding mode
of compound 4b towards the active site of BuChE is −8.90
kcal/ mol, consistent with the results of enzyme inhibition
assay that compound 4b is more active to BuChE than to
AChE. The MOLCAD cavity depth potential surface also
shows that compound 4b extends into the deep cavity of
the binding pocket of BuChE (Figure 6B). Compound 4b
forms three hydrogen bonds with the binding pocket of
BuChE. The CO motif of compound 4b forms a hydrogen
bond with the backbone NH of Gly117 and another one





R3 IC50 (μM) a for AChE IC50 (μM) for BuChE Selectivity for BuChE/AChE
1a
N





H 73.72 ± 1.36 36.98 ± 0.56 0.50
1c
N
H 81.92 ± 2.04 35.49 ± 1.68 0.43
1d
N
H 79.34 ± 5.78 42.98 ± 1.76 0.54
1e
N O
H 95.35 ± 1.70 >100 >1.05
2a
N
CH3 2.34 ± 0.20 10.89 ± 0.20 4.66
2b
N
CH3 2.40 ± 0.49 6.79 ± 0.56 2.83
2c
N
CH3 4.20 ± 0.29 7.21 ± 0.75 1.72
2d
N
CH3 7.00 ± 0.07 10.62 ± 0.22 1.53
2e
N O
CH3 7.76 ± 2.36 >100 >12.89
3a
N
5.84 ± 1.19 4.66 ± 0.64 0.80
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Table 2 Inhibition of AChE and BuChE activities of title compounds (Continued)
3b
N
6.00 ± 0.33 1.54 ± 0.14 0.26
3c
N
4.36 ± 0.58 3.05 ± 0.13 0.70
3d
N
3.70 ± 0.16 1.73 ± 0.08 0.47
3e
N O
74.73 ± 4.07 >100 >1.34
4a
N
2.63 ± 0.07 1.49 ± 0.03 0.57
4b
N
2.60 ± 0.13 0.51 ± 0.01 0.20
4c
N
5.85 ± 0.32 2.89 ± 0.07 0.49
4d
N
55.34 ± 8.15 5.61 ± 0.08 0.10
4e
N O
24.16 ± 0.40 8.83 ± 0.36 0.37
Galanthamine · HBr 1.12 ± 0.02 29.99 ± 0.05 26.78
aData are means ± standard deviation of triplicate independent experiments.
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In addition, The OH groups at the aromatic ring may also
interact with Ser198 by forming a hydrogen bond, leading
to the attenuation of catalytic ability of BuChE. These
H-bonds are believed to contribute to the higher affinity
of compound 4b towards BuChE, which explains why it is
more potent than towards AChE.Experimental
Chemistry
Melting points were measured in X-4 micro-melting
point instrument and are uncorrected. IR spectra were
taken on Nicolet ESP 360 FI-IR. Direct MS spectra were
performed on ESQUIRE HTC instrument in positive
mode using KBr pellets. 1H NMR and 13C NMR spectra
were recorded in CDCl3 or Acetone on Bruker AVANCEAV 500/125 MHz instruments. Chemical shifts are
reported as δ ppm using tetramethylsilane (TMS) as the
internal standard and couplings expressed in Hertz. Spin
multiplicities are given as follows: s (singlet), d (doublet),
t (triplet), m (multiplet), or br (broad). Reactions were
monitored by thin layer chromatography (TLC) using 0.2
mm Polygram Sil silica gel G254 pre-coated plates with
visualization by irradiation with a short-wavelength UV
light. Column chromatography was accomplished on
Qingdao silica gel (100–200, 200–300 or 300–400 mesh).
The process for preparing of title compounds can be
found in Additional file 1. HSQC and HMBC spectral ana-
lysis of 2c was taken and the data was showed in Table 1.
Enzyme inhibition assays
Electric-eel AChE (EC 3.1.1.7), horse-serum BuChE
(EC3.1.1.8), acetylthiocholine iodide, butyrylthiocholine
Figure 2 Effects of substitution in position 2 of xanthone against AChE and BuChE, respectively. 1, 2, 3, 4 represent hydroxyl, methoxyl,
allyloxy, prenylated oxyl substituted in the position 3 of xanthone, respectively. a, b, c, d, e represent diethylamine methyl, dimethylamine methyl,
pyrrolidinyl methyl, piperidinyl methyl, morpholino methyl substituted in the position 2 of xanthone, respectively.
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Galanthamine hydrobromide (galanthamine · HBr) were
purchased from the Sigma. All other agents were analyt-
ical grade. AChE and BuChE inhibiting activities were
measured by the slight modified spectrophotometric
method of Ellman using a 96-well plate reader [36].
Acetylthiocholine iodide and butyrylthiocholine chloride
were used as substrates for AChE and BuChE, respect-
ively. The total volume of tested solution in each well
was 150 μL. These containing phosphate buffer 118 μLFigure 3 Effects of substitution in position 3 of xanthone against ACh
allyloxy, prenylated oxyl substituted in the position 3 of xanthone, respectiv
pyrrolidinyl methyl, piperidinyl methyl, morpholino methyl substituted in th(0.1 M, pH 8.0), DTNB 6 μL(4 mg/mL for AChE or
8 mg/mL for BuChE), different concentration of tested
compounds solution 15 μL and AChE or BuChE solu-
tion 5 μL, were mixed and incubated for 15 min at 37°C.
The reaction was then measured followed by the
addition of acetylthiocholine or butyrythiocholine solu-
tion (2 mg/mL or 4 mg/mL, respectively) 6 μL. The hy-
drolysis of acetylthiocholine and butyrylthiocholine
were monitored by the formation of yellow 5-thio-2-
nitrobenzoate anion as a result of the reaction betweenE and BuChE, respectively. 1, 2, 3, 4 represent hydroxyl, methoxyl,
ely. a, b, c, d, e represent diethylamine methyl, dimethylamine methyl,
e position 2 of xanthone, respectively.















































Figure 4 Lineweaver-Burk plots of AChE and BuChE inhibitory activity in the presence of compound 4b.
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of acetylthiocholine and butyrylthiocholine by AChE
and BuChE, respectively, at the wavelength of 405 nm
for 1 min. Tested compounds and the positive control
(Galantha-mine · HBr) were dissolved in DMSO at a con-
centration of 10 mM before used and diluted in phosphate
buffer to the required concentration. All the reactions
were performed in triplicate in 96-well microplates in
Microplate reader ELX808™ (BioTek). The concentrations
of tested compounds that inhibited the hydrolysis of sub-
strates (acetylthiocholine and butyrylthiocholine) by 50%
(IC50) were determined by monitoring the effect of in-
creasing concentrations of these compounds in the assays
on the inhibition values. The IC50 values were then calcu-
lated using the Origin 7.5.Figure 5 The binding mode research of compound 4b on AChE by do
the active site for compound 4b. (B) The MOLCAD surfaces displayed with
surfaces of the binding pocket displayed with lipophilic potential.Enzyme kinetic assays
The enzyme kinetic assays were followed the same method
and the similar procedure. The total volume of tested solu-
tion in each well was also 150 μL. These containing phos-
phate buffer 118 μL(0.1 M, pH 8.0), DTNB 6 μL(4 mg/mL
for AChE or 8 mg/mL for BuChE), different concentration
of tested compounds solution 15 μL and AChE or BuChE
solution 5 μL, were mixed and incubated for 15 min at
37°C. The reaction was then measured by the addition of
different concentration of (2.0, 1.6, 1.2, 0.8, 0.4, 0.2 mg/mL)
acetylthiocholine or (4.0, 3.2, 2.4, 1.6, 0.8, 0.4 mg/mL)
butyrythiocholine solution with the volume of 6 μL. The
hydrolysis of acetylthiocholine and butyrylthiocholine were
monitored in 96-well micro-plates in Microplate reader
ELX808™ (BioTek) at the wavelength of 405 nm for 1 min.cking simulations. (A) Binding interactions with selected residues of
cavity depth potential of the binding pocket. (C) The MOLCAD
Figure 6 The binding mode research of compound 4b on BuChE by docking simulations. (A) The binding interactions with selected
residues of the active site for compound 4b. (B) The MOLCAD surfaces displayed with cavity depth potential of the binding pocket. (C) The
MOLCAD hydrogen bonding surfaces of the binding pocket.
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velocity versus substrate.
Docking studies
Docking studies were performed using the molecular
modeling software package SYBYL 8.0 (Tripos, USA). The
ligand was charged using the Gasteiger-Huckel and then
subjected to energy minimization using the Powell’s
method with standard Tripos force field with a 0.01 kcal/
(mol*Å) gradient. The minimum-energy structure was
used for the subsequent docking calculations. The crystal
structures of AChE and BuChE retrieved from the Protein
Data Bank (PDB) were used as the initial 3D structure. For
AChE, the crystallographic ligand was extracted from the
active site, and the resi-dues within a 6.5 Å radius around
the enzyme were defined as the active site. For BuChE, the
choline, water and cocrystallized small molecules were re-
moved from the p-rotein structure firstly. After the
addition of hydrogen and charges, the protein structure
was minimized with Amber FF99 force field and 1000
steps. The active site of BuChE was generated by auto-
matic mode implemented in Surflex-Dock program in
SYBYL with default parameters. The Surflex-Dock pro-
gram was used for the docking calculations and MOLCAD
surfaces were generated for visualizing the binding mode
of the docked protein-ligand complexes.
Conclusions
In conclusions, a series of Mannich bases of 1, 3-
dihydroxyxanthone derivatives were designed, synthesized
and subjected to pharmacological evaluation. The results
showed that the synthetic compounds possessed good
to moderate cholinesterases inhibitory potency. The
1-hydroxy-3-methoxy substituted xanthone derivatives
(2a ~ 2e) showed higher inhibitory effects on AChE. And
the compounds with prenyl substitution in the position 3of xanthone showed higher BuChE inhibitory potency. In
addition, the compounds with diethylamine methyl at the
end of the side chain in the position 2 of xanthone
possessed higher inhibitory activity. Moreover, the com-
pounds with alkyl substitutions in the position 3 of 1,3-
dihydroxyxanthone showed higher potent inhibitory
activities compared to 1a ~ 1e compounds with hydroxy
in the position 3. Kinetic analysis suggested that the the
Mannich base compound inhibited both cholinesterases
in mixed-type manners, suggesting they might simul-
taneously interact with the AS and PAS of both en-
zymes. Molecular docking studies were carried out to
further investigate the binding modes of Mannich base
derivatives with both cholinesterases, and the result was
consistent with that of kinetic analysis. Finally, our re-
sults indicated that these new compounds represent
useful templates for the development of new anti-AD
agents.Additional file
Additional file 1: contains the experimental details of preparation
and characterization of the relational compounds in the paper.Abbreviations
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